Hydrocortisone Acetate 1% Topical

Indications

Hydrocortisone Acetate 1% Topical is used for: Corticosteroid-responsive dermatoses, Contact allergic dermatitis, Eczema - atopic; infantile; discoid; stasis, Seborrheic dermatitis, Skin irritations, itching and rashes, for example those caused by insect bites, minor thermal burns, sunburn, etc.

Adult Dose

Corticosteroid-responsive Dermatoses Adult: Apply a thin film onto affected area 2-4 times daily. Dosage and treatment duration may vary according to the severity of the condition and patient response.

Child Dose

Atopic Dermatitis <3 months: Safety and efficacy not established >3 months: Apply film to affected area q12hr Corticosteroid-responsive Dermatoses Apply q6-12hr Dosing considerations Limit to the minimum amount necessary for therapeutic efficacy

Renal Dose

Administration

Contra Indications

Viral/fungal infections, tubercular or syphilitic lesions, bacterial infections unless used in conjunction with appropriate chemotherapy.

Precautions

Chronic topical corticosteroid therapy may interfere with growth and development in children Use lower potency in children; may absorb proportionally larger amounts after topical application and may cause systemic effects Occlusive dressings, prolonged use, application to large surface areas, or application to denuded skin, may increase percutaneous absorption, which may result in Cushing syndrome, glycosuria, and hyperglycemia Prolonged use may increase risk of Kaposi's sarcoma Prolonged use may increase risk of secondary infection, may mask acute infection, limit response to vaccines, and prolong or exacerbate viral infections; avoid exposure to measles or chickenpox while receiving therapy; not for the treatment of ocular herpes simplex, cerebral malaria, fungal infections, or viral hepatitis; observe patients with latent tuberculosis closely; restrict use in active tuberculosis Allergic contact dermatitis may occur; diagnosed as failure to heal rather than exacerbation; discontinue therapy and treat appropriately if it occurs Local desensitization (irritation, redness) reported; discontinue if it occurs Use caution in patients with diabetes, cardiovascular disease, hepatic impairment, myocardial infarction, myasthenia gravis, osteoporosis, ocular disease, renal impairment, or thyroid disease

Pregnancy-Lactation

Pregnancy There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids; corticosteroids generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels; topical corticosteroids should be used during pregnancy only if potential benefits justify potential risk to fetus; should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time Lactation Not know whether topical administration could result in sufficient systemic absorption to produce detectable quantities in breast milk; systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on infant; nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman

Interactions

Side Effects

Side effects of Hydrocortisone Acetate 1% Topical : Skin atrophy, Striae, Acneform lesions, Perioral dermatitis, Folliculitis, Itching, Pigmentation changes, HPA suppression (with higher potency used >2 wk)

Mode of Action

Hydrocortisone is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its anti-inflammatory action is due to the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes Inhibits macrophage accumulation in inflamed areas Reduces leukocyte adhesion to capillary endothelium Reduces capillary wall permeability and edema formation Decreases complement components and antagonizes histamine activity and release of kinin from substrates Reduces fibroblast proliferation, collagen deposition, and subsequent scar tissue formation